(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 August 2009 (13.08.2009)

PCT

(10) International Publication Number
WO 2009/098612 A3

(51) International Patent Classification:
A61K 31/437 (2006.01) *C07D 471/04* (2006.01)
A61P 29/00 (2006.01)

(21) International Application Number:
PCT/IB2009/050351

(22) International Filing Date:
28 January 2009 (28.01.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/025,879 4 February 2008 (04.02.2008) US

(71) Applicant *(for all designated States except US)*: **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **BUTCHER, Kenneth, John** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agent: **DROUIN, Stephane**; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*


Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
8 October 2009

(54) Title: POLYMORPHIC FORM OF A [1, 2, 4] TRIAZOLO [4, 3-A] PYRIDINE DERIVATIVE FOR TREATING INFLAMMATORY DISEASES



(I)

(57) Abstract: The present invention relates to a polymorphic form B of Λ/-[3-tert-butyl-1-(3- chloro-4-hydroxyphenyl)-1 H-pyrazol-5-yl]-*N*-{2-[(3-{2-[(2-hydroxyethyl)sulfanyl] phenyl}[1,2.4]triazolo[4,3-a]pyridin-6-yl)sulfanyl]benzyl}urea (I) as defined herein. This polymorph is useful in the treatment of various conditions, particularly in the treatment of inflammatory conditions such as chronic obstructive pulmonary disease.

WO 2009/098612 A3